10 December 2014
A team at Indiana University (IU) and the German Research Center for Environmental Health has created a new treatment designed to prevent adult-onset diabetes and obesity. The research essentially cured lab animals of obesity, diabetes and associated lipid abnormalities through improved glucose sensitivity, reduced appetite and enhanced calorie burning.
From their preclinical trial work, the team found that the new peptide, which is a molecular integration of three gastrointestinal hormones, was able to reduce blood sugar levels and body fat better than current drugs on the market.
The study, led by IU distinguished professor of chemistry Richard DiMarchi and director of the Institute for Diabetes and Obesity at the German Research Center for Environmental Health Matthias Tschop, shows results never achieved before.
Published in Nature Medicine, the research found that the new single-cell molecules with triple-hormone action was able to reduce body weight by about 30 per cent, almost twice as much as the GLP-1/GIP double hormone.
The molecules are called triple agonists, which combine three hormones that can then bind to and activate receptors to produce certain biological responses.
Posted by Edward Bartel
Health News is provided by Adfero in collaboration with Spire Healthcare. Please note that all copy above is ©Adfero Ltd. and does not reflect views or opinions of Spire Healthcare unless explicitly stated. Additional comments on the page from individual Spire consultants do not necessarily reflect the views or opinions of other consultants or Spire Healthcare.